143 related articles for article (PubMed ID: 16280111)
1. Farnesyl transferase inhibition in hematologic malignancies.
Karp JE
J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S37-40. PubMed ID: 16280111
[No Abstract] [Full Text] [Related]
2. Farnesyltransferase inihibitors in hematologic malignancies.
Harousseau JL
Blood Rev; 2007 Jul; 21(4):173-82. PubMed ID: 17293017
[TBL] [Abstract][Full Text] [Related]
3. Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.
Karp JE; Lancet JE
Future Oncol; 2005 Dec; 1(6):719-31. PubMed ID: 16556050
[TBL] [Abstract][Full Text] [Related]
4. Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.
Martinelli G; Iacobucci I; Paolini S; Ottaviani E
Clin Adv Hematol Oncol; 2008 Apr; 6(4):303-10. PubMed ID: 18496498
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials referral resource. Clinical trials with the farnesyl transferase inhibitor R115777.
Wright J; Blatner GL; Cheson BD
Oncology (Williston Park); 1999 Nov; 13(11):1527, 1530, 1533. PubMed ID: 10581601
[No Abstract] [Full Text] [Related]
6. Farnesyl transferase inhibitors in myeloid malignancies.
Lancet JE; Karp JE
Blood Rev; 2003 Sep; 17(3):123-9. PubMed ID: 12818222
[TBL] [Abstract][Full Text] [Related]
7. Clinical activity of tipifarnib in hematologic malignancies.
Jabbour E; Kantarjian H; Cortes J
Expert Opin Investig Drugs; 2007 Mar; 16(3):381-92. PubMed ID: 17302532
[TBL] [Abstract][Full Text] [Related]
8. Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies.
Karp JE; Lancet JE
Cancer Invest; 2007 Sep; 25(6):484-94. PubMed ID: 17882662
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
Armand JP; Burnett AK; Drach J; Harousseau JL; Löwenberg B; San Miguel J
Oncologist; 2007 Mar; 12(3):281-90. PubMed ID: 17405892
[TBL] [Abstract][Full Text] [Related]
10. Tipifarnib: farnesyl transferase inhibition at a crossroads.
Mesa RA
Expert Rev Anticancer Ther; 2006 Mar; 6(3):313-9. PubMed ID: 16503848
[TBL] [Abstract][Full Text] [Related]
11. E2902: A Phase III randomized study of farnesyl transferase inhibitor R115777 in acute myeloid leukemia patients in second or subsequent remission or in remission after primary induction failure or patients over age 60 in first remission.
Clin Adv Hematol Oncol; 2007 Jan; 5(1):13-4. PubMed ID: 17339821
[No Abstract] [Full Text] [Related]
12. Farnesyltransferase inhibitors in myelodysplastic syndrome.
Feldman EJ
Curr Hematol Malig Rep; 2006 Mar; 1(1):20-4. PubMed ID: 20425327
[TBL] [Abstract][Full Text] [Related]
13. Farnesyltransferase inhibitors.
Kurzrock R
Clin Adv Hematol Oncol; 2005 Mar; 3(3):161-2. PubMed ID: 16166986
[No Abstract] [Full Text] [Related]
14. Tipifarnib (Janssen Pharmaceutica).
Norman P
Curr Opin Investig Drugs; 2002 Feb; 3(2):313-9. PubMed ID: 12020065
[TBL] [Abstract][Full Text] [Related]
15. Role of farnesyltransferase inhibitors in hematologic malignancies.
Santos ES; Rosenblatt JD; Goodman M
Expert Rev Anticancer Ther; 2004 Oct; 4(5):843-56. PubMed ID: 15485318
[TBL] [Abstract][Full Text] [Related]
16. Molecule of the month. Tipifarnib.
Drug News Perspect; 2005 Apr; 18(3):204. PubMed ID: 15915222
[No Abstract] [Full Text] [Related]
17. Plexiform neurofibromas, trial design, and the definitions of "progression" and "treatment failure".
Prados MD
Neuro Oncol; 2014 May; 16(5):617-8. PubMed ID: 24714524
[No Abstract] [Full Text] [Related]
18. Bendamustine: a novel cytotoxic agent for hematologic malignancies.
Blumel S; Goodrich A; Martin C; Dang NH
Clin J Oncol Nurs; 2008 Oct; 12(5):799-806. PubMed ID: 18842536
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine: a new therapeutic option for hematologic malignancies.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):631-3. PubMed ID: 18827785
[No Abstract] [Full Text] [Related]
20. Targeting the process of farynesylation for therapy of hematologic malignancies.
Karp JE; Lancet JE
Curr Mol Med; 2005 Nov; 5(7):643-52. PubMed ID: 16305490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
